56.56
price down icon1.27%   -0.73
after-market 시간 외 거래: 56.60 0.04 +0.07%
loading
전일 마감가:
$57.29
열려 있는:
$57.28
하루 거래량:
1.06M
Relative Volume:
0.52
시가총액:
$10.85B
수익:
$2.95B
순이익/손실:
$523.88M
주가수익비율:
21.03
EPS:
2.69
순현금흐름:
$620.18M
1주 성능:
-2.87%
1개월 성능:
+2.84%
6개월 성능:
-9.55%
1년 성능:
-32.74%
1일 변동 폭
Value
$56.48
$57.55
1주일 범위
Value
$56.48
$59.35
52주 변동 폭
Value
$52.93
$94.85

바이오마린 Stock (BMRN) Company Profile

Name
명칭
Biomarin Pharmaceutical Inc
Name
전화
(415) 506-6700
Name
주소
105 DIGITAL DRIVE, NOVATO, CA
Name
직원
3,040
Name
트위터
Name
다음 수익 날짜
2024-10-29
Name
최신 SEC 제출 서류
Name
BMRN's Discussions on Twitter

BMRN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
BMRN
Biomarin Pharmaceutical Inc
56.56 11.17B 2.95B 523.88M 620.18M 2.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

바이오마린 Stock (BMRN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-07-03 재개 Morgan Stanley Overweight
2025-02-24 업그레이드 Oppenheimer Perform → Outperform
2024-11-15 개시 Wolfe Research Outperform
2024-10-30 다운그레이드 William Blair Outperform → Mkt Perform
2024-10-10 재개 Raymond James Outperform
2024-08-20 업그레이드 Bernstein Mkt Perform → Outperform
2024-05-17 다운그레이드 Robert W. Baird Outperform → Neutral
2024-05-14 개시 Evercore ISI Outperform
2023-11-15 개시 Wells Fargo Overweight
2023-10-23 업그레이드 Bernstein Underperform → Mkt Perform
2023-09-28 개시 Raymond James Mkt Perform
2023-09-18 개시 UBS Buy
2023-07-27 개시 Scotiabank Sector Perform
2023-07-05 업그레이드 BMO Capital Markets Market Perform → Outperform
2023-06-14 재개 Credit Suisse Outperform
2023-03-21 개시 Bernstein Underperform
2023-02-22 다운그레이드 Oppenheimer Outperform → Perform
2023-02-21 개시 Citigroup Neutral
2023-01-30 개시 BMO Capital Markets Market Perform
2023-01-18 개시 Canaccord Genuity Hold
2022-10-31 업그레이드 Oppenheimer Perform → Outperform
2022-07-13 개시 Cantor Fitzgerald Overweight
2022-06-13 재개 Wedbush Neutral
2022-04-25 업그레이드 Morgan Stanley Equal-Weight → Overweight
2021-11-22 업그레이드 William Blair Mkt Perform → Outperform
2021-10-07 재개 Jefferies Buy
2021-09-09 업그레이드 Stifel Hold → Buy
2021-06-04 재개 Robert W. Baird Outperform
2021-04-26 재개 Credit Suisse Outperform
2021-03-04 재개 Guggenheim Buy
2021-03-01 업그레이드 Evercore ISI In-line → Outperform
2020-08-20 다운그레이드 Citigroup Buy → Neutral
2020-08-20 다운그레이드 William Blair Outperform → Mkt Perform
2020-08-19 다운그레이드 Evercore ISI Outperform → In-line
2020-08-19 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2020-08-19 다운그레이드 Stifel Buy → Hold
2020-07-08 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2020-07-06 재확인 Citigroup Buy
2020-01-28 개시 BMO Capital Markets Market Perform
2020-01-27 개시 BMO Capital Markets Market Perform
2020-01-24 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2019-11-27 업그레이드 Barclays Equal Weight → Overweight
2019-11-12 개시 SunTrust Buy
2019-10-17 재개 BofA/Merrill Buy
2019-05-23 재개 Citigroup Buy
2019-04-09 재개 Raymond James Outperform
2019-01-02 다운그레이드 Raymond James Outperform → Mkt Perform
2018-12-14 개시 Wolfe Research Outperform
2018-10-01 개시 Cantor Fitzgerald Overweight
2018-08-07 재확인 Stifel Buy
2018-08-03 재확인 Stifel Buy
모두보기

바이오마린 주식(BMRN)의 최신 뉴스

pulisher
Jul 19, 2025

What analysts say about BioMarin Pharmaceutical Inc. stockTremendous growth potential - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

BioMarin Bets On Growth, But Competition Keeps Pressure On - Finimize

Jul 19, 2025
pulisher
Jul 19, 2025

What drives BioMarin Pharmaceutical Inc. stock priceConsistently superior profits - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

BioMarin Pharmaceutical Inc. Stock Analysis and ForecastUnmatched market performance - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Is BioMarin Pharmaceutical Inc. a good long term investmentDynamic investment growth - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 17, 2025

BioMarin’s BMN 349 Study: A Potential Game-Changer in Genetic Disorder Treatment - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Morgan Stanley Sees Rebound Potential in BioMarin (BMRN), Highlights Underappreciated Voxzogo Upside - Yahoo

Jul 17, 2025
pulisher
Jul 16, 2025

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt? - 富途牛牛

Jul 16, 2025
pulisher
Jul 16, 2025

Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

Wall Street Analysts Think BioMarin (BMRN) Could Surge 70.77%: Read This Before Placing a Bet - Zacks Investment Research

Jul 16, 2025
pulisher
Jul 15, 2025

BioMarin stock maintains Outperform rating at Wolfe Research amid PKU market competition By Investing.com - Investing.com South Africa

Jul 15, 2025
pulisher
Jul 15, 2025

BioMarin stock maintains Outperform rating at Wolfe Research amid PKU market competition - Investing.com Nigeria

Jul 15, 2025
pulisher
Jul 14, 2025

What makes BioMarin Pharmaceutical Inc. stock price move sharplyFree Step-by-Step Investment Guide - beatles.ru

Jul 14, 2025
pulisher
Jul 14, 2025

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - NewsBreak: Local News & Alerts

Jul 14, 2025
pulisher
Jul 13, 2025

BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma - MSN

Jul 13, 2025
pulisher
Jul 11, 2025

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2025 Earnings Call Transcript - MSN

Jul 11, 2025
pulisher
Jul 11, 2025

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - sharewise.com

Jul 11, 2025
pulisher
Jul 10, 2025

Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Jul 10, 2025
pulisher
Jul 09, 2025

10 Best Growth Stocks to Buy With Huge Upside Potential - Insider Monkey

Jul 09, 2025
pulisher
Jul 08, 2025

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock - Yahoo Finance

Jul 08, 2025
pulisher
Jul 03, 2025

BioMarin’s BMN 349 Study: A New Frontier in Genetic Mutation Treatment - TipRanks

Jul 03, 2025
pulisher
Jul 03, 2025

BioMarin stock rating initiated at Overweight by Morgan Stanley on Voxzogo growth - Investing.com

Jul 03, 2025
pulisher
Jul 03, 2025

The Top 12 Companies Hiring in Biopharma Now - BioSpace

Jul 03, 2025
pulisher
Jul 02, 2025

The Best Biotech Stocks to Buy - Morningstar

Jul 02, 2025
pulisher
Jul 01, 2025

BioMarin Pharmaceutical completes acquisition of Inozyme Pharma - grafa.com

Jul 01, 2025
pulisher
Jul 01, 2025

BioMarin Pharmaceutical Closes Acquisition of Inozyme Pharma - MarketScreener

Jul 01, 2025
pulisher
Jul 01, 2025

BioMarin Acquires Inozyme for $270M, Gains Late-Stage Enzyme Therapy for Untreated Rare Disease - Stock Titan

Jul 01, 2025
pulisher
Jul 01, 2025

BioMarin completes acquisition of Inozyme Pharma, triggers delisting from Nasdaq - Investing.com

Jul 01, 2025
pulisher
Jun 30, 2025

BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell 1000 Defensive Index - MarketScreener

Jun 30, 2025
pulisher
Jun 28, 2025

BioMarin’s ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A - MSN

Jun 28, 2025
pulisher
Jun 28, 2025

11 Most Undervalued US Stocks According to Analysts - Insider Monkey

Jun 28, 2025
pulisher
Jun 26, 2025

Pfizer's bleeding disorder therapy succeeds in trial with patients with certain antibodies - Reuters

Jun 26, 2025
pulisher
Jun 25, 2025

BioMarin sees long-term strength in Roctavian data - The Pharma Letter

Jun 25, 2025
pulisher
Jun 24, 2025

BioMarin’s hemophilia gene therapy shows sustained results at 5 years - Investing.com

Jun 24, 2025
pulisher
Jun 23, 2025

Barclays Initiates BioMarin Pharmaceutical Inc. (BMRN) with a Buy Rating - Yahoo Finance

Jun 23, 2025
pulisher
Jun 22, 2025

2 Reasons to Watch BMRN and 1 to Stay Cautious - Yahoo Finance

Jun 22, 2025
pulisher
Jun 20, 2025

Inozyme Pharma Halts Annual Meeting as BioMarin Acquisition Nears Completion - Stock Titan

Jun 20, 2025
pulisher
Jun 18, 2025

BioMarin Generates Patient Experience Data With Early And Often Engagement - Clinical Leader

Jun 18, 2025
pulisher
Jun 15, 2025

Jim Cramer on BioMarin: “I Don’t Think It Works Now” - MSN

Jun 15, 2025
pulisher
Jun 14, 2025

BioMarin’s SWOT analysis: stock growth potential amid rare disease focus - Investing.com

Jun 14, 2025
pulisher
Jun 13, 2025

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - MSN

Jun 13, 2025
pulisher
Jun 12, 2025

Jim Cramer Discussed These 16 Stocks Recently - Insider Monkey

Jun 12, 2025
pulisher
Jun 12, 2025

Phenylktonuria Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Erytech Pharma SA, Homology Medicines Inc., Synlogic Inc., BioMarin Pharmaceuticals - Barchart.com

Jun 12, 2025
pulisher
Jun 12, 2025

Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs - Benzinga

Jun 12, 2025
pulisher
Jun 10, 2025

BioMarin Pharmaceutical: Hold Rating Maintained Amid Competitive Pressures and New Data Insights - TipRanks

Jun 10, 2025

바이오마린 (BMRN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
자본화:     |  볼륨(24시간):